Crinum Latifolium Leave Extracts Suppress Immune Activation Cascades in Peripheral Blood Mononuclear Cells and Proliferation of Prostate Tumor Cells
2011

Crinum Latifolium Leaf Extracts and Their Effects on Immune Activation and Prostate Tumor Cells

publication 10 minutes Evidence: moderate

Author Information

Author(s): Jenny Marcel, Wondrak Angela, Zvetkova Elissaveta, Tram Nguyen Thi Ngoc, Phi Phan Thi Phi, Schennach Harald, Culig Zoran, Ueberall Florian, Fuchs Dietmar

Primary Institution: Innsbruck Medical University

Hypothesis

The study investigates the effects of Crinum latifolium leaf extracts on immune activation and the proliferation of prostate tumor cells.

Conclusion

Crinum latifolium leaf extracts inhibit tumor cell growth and enhance immune function, suggesting potential antitumor properties.

Supporting Evidence

  • The aqueous extract of Crinum latifolium showed potent antioxidant activity with an ORAC value of 1610 ± 150 μmol Trolox equivalents/g.
  • The extract suppressed IDO-mediated tryptophan degradation in PBMC at IC50 doses of 241 ± 57 μg/ml and 92 ± 20 μg/ml.
  • Neopterin formation was inhibited in a dose-dependent manner in mitogen-stimulated PBMC.
  • The extract inhibited the proliferation of prostate carcinoma PC3 cells with an IC50 of 4.5 ± 0.8 mg/ml.
  • Crinum latifolium extracts demonstrated significant anti-inflammatory effects on PBMC.

Takeaway

This study shows that a plant called Crinum latifolium can help stop cancer cells from growing and also help the immune system work better.

Methodology

The study used in vitro assays to evaluate the antioxidant and anti-inflammatory effects of Crinum latifolium extracts on peripheral blood mononuclear cells and prostate cancer cell lines.

Limitations

The study's findings are based on in vitro experiments, and further in vivo studies are needed to confirm the results.

Participant Demographics

Healthy donors provided blood for PBMC isolation.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3797/scipharm.1011-13

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication